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Dopaminergic Influences on Emotional Decision Making in
Euthymic Bipolar Patients
Katherine E Burdick*,1, Raphael J Braga2,3,4, Chaya B Gopin5 and Anil K Malhotra2,3,4
1Department of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Department of Psychiatry
Research, The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA; 3The Feinstein Institute for Medical
Research, Manhasset, NY, USA; 4Department of Psychiatry, Hofstra University School of Medicine, Hempstead, NY, USA; 5Department of
Psychiatry, Weill Cornell Medical College, New York, NY, USA
We recently reported that the D2/D3 agonist pramipexole may have pro-cognitive effects in euthymic patients with bipolar disorder
(BPD); however, the emergence of impulse-control disorders has been documented in Parkinson’s disease (PD) after pramipexole
treatment. Performance on reward-based tasks is altered in healthy subjects after a single dose of pramipexole, but its potential to induce
abnormalities in BPD patients is unknown. We assessed reward-dependent decision making in euthymic BPD patients pre- and post
8 weeks of treatment with pramipexole or placebo by using the Iowa Gambling Task (IGT). The IGT requires subjects to choose among
four card decks (two risky and two conservative) and is designed to promote learning to make advantageous (conservative) choices over
time. Thirty-four BPD patients completed both assessments (18 placebo and 16 pramipexole). Baseline performance did not differ by
treatment group (F¼ 0.63; p¼ 0.64); however, at week 8, BPD patients on pramipexole demonstrated a significantly greater tendency to
make increasingly high-risk, high-reward choices across the five blocks, whereas the placebo group’s pattern was similar to that reported
in healthy individuals (treatment time block interaction, po0.05). Analyses of choice strategy using the expectancy valence model
revealed that after 8 weeks on pramipexole, BPD patients attended more readily to feedback related to gains than to losses, which could
explain the impaired learning. There were no significant changes in mood symptoms over the 8 weeks, and no increased propensity
toward manic-like behaviors were reported. Our results suggest that the enhancement of dopaminergic activity influences risk-associated
decision-making performance in euthymic BPD. The clinical implications remain unknown.
Neuropsychopharmacology (2014) 39, 274–282; doi:10.1038/npp.2013.177; published online 9 October 2013
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INTRODUCTION
Dopamine (DA) is critical in normal cognitive functioning
and reward-based learning (Balleine et al, 2007; Schultz,
2006). Although several studies, in both animals and
humans, have demonstrated beneficial cognitive effects of
pro-dopaminergic agents on measures of attention and
working memory (Costa et al, 2009; Granon et al, 2000;
Mattay et al, 2000; Mehta et al, 2000), there have also been
reports of rare but concerning side effects, including
induced impulse-control disorders in individuals with no
prior history of such difficulties (Dodd et al, 2005; Driver-
Dunckley et al, 2007; Giovannoni et al, 2000; Klos et al,
2005; Madden et al, 2010; McKeon et al, 2007; Munhoz et al,
2009; Potenza et al, 2007; Riba et al, 2008; Voon et al, 2006b;
Weintraub et al, 2006).
For example, the DA D2/D3 receptor agonist, pramipexole,
as well as other DA receptor agonists have been implicated in
the emergence of risk-seeking behaviors, such as pathologi-
cal gambling in multiple case reports and cross-sectional
studies in patients with Parkinson’s disease (PD) (Bodi et al,
2009; Dodd et al, 2005; Lader, 2008; Pontone et al, 2006;
Potenza et al, 2007; Voon et al, 2006a, 2006b; Weintraub
et al, 2006, 2010). A purported mechanism for this effect is
related to pramipexole’s high selective affinity for D3
receptors, which are primarily expressed in the mesocorti-
colimbic DA pathway—a circuitry that is active during
impulsive decision making (Madden et al, 2010). Indeed,
several studies that have used pramipexole in single-dose
challenge paradigms have confirmed its actions on reward-
related neural networks, primarily at low doses and in
healthy individuals (Riba et al, 2008; Ye et al, 2011). Low
doses of pramipexole (eg, 0.25–0.5mg) are thought to
influence reward via a paradoxical effect related to activation
of the presynaptic D2 autoreceptor, resulting in a blockade
of phasic DA release and a blunted response to rewarding
stimuli (Riba et al, 2008). In contrast, higher doses
of pramipexole, including those in the range used to treat
PD, act as specific agonists both presynaptically and
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postsynaptically to enhance dopaminergic activity (Mierau
et al, 1995), which may be more relevant to the potential to
induce compulsive behaviors, such as pathological gambling,
although the specific distinctions have not been directly
demonstrated.
Although pramipexole has received indications for PD
and restless legs syndrome, it has also been used off-label in
several studies as an antidepressant in patients with major
mood disorders (Aiken, 2007). Preliminary data suggest that
pramipexole is safe and effective in treating depression
when added to mood stabilizers in patients with bipolar
disorder (BPD) (Goldberg et al, 2004; Zarate et al, 2004)
at least in short-term trials; however, less is known over
longer durations (Cassano et al, 2004). Given the data
regarding pramipexole’s effect on impulse-control and
reward-based decision making in patients with PD,
particular caution should be taken when using it in patients
with BPD, who are predisposed to risky behaviors
associated with impaired decision making (Lader, 2008).
Bipolar patients exhibit impulsive behaviors, such as
increased spending and hypersexual activity during periods
of manic exacerbations, and when tested in the laboratory
they consistently demonstrate deficits on decision-making
tasks compared with healthy controls (Adida et al, 2008,
2011; Jollant et al, 2007; Martino et al, 2011; Yechiam et al,
2008). Even during periods of remission, patients with BPD
demonstrate decreased reward-based learning (Pizzagalli
et al, 2008), which may be related to reduced sensitivity to
emotional contexts that highlight rewards or punishments
(Chandler et al, 2009). Convergent evidence from research
on the behavioral activation system (BAS) suggests that
patients with BPD report elevated sensitivity to reward-
relevant stimuli, an abnormality which may also be related
to risk for developing BPD (Johnson et al, 2012). More
research is required to better understand the exact nature of
reward-related abnormalities in BPD.
There is a paucity of data on the potential for pramipexole
to cause impulse-control disorders in patients with BPD.
A single case report described a 56-year-old male with
bipolar II disorder, who developed pathological gambling
after 44 weeks of treatment with pramipexole. Upon
drug discontinuation, the gambling behavior was abruptly
extinguished, implicating pramipexole as causative
(Strejilevich et al, 2011). As there are no empirical data on
the prevalence of pramipexole exposure in BD patients in the
community, it is impossible to establish the rarity of such a
case or to compare it with similar side effects associated with
other medications. Nonetheless, given the convergent data in
PD and in healthy control subjects alongside a predisposi-
tion toward impulsive behaviors in BPD (Adida et al, 2008,
2011; Jollant et al, 2007; Martino et al, 2011; Yechiam et al,
2008), it would be reasonable to predict that BPD patients
might be especially susceptible to the development of
impulse-control disorders or behaviors associated with poor
emotional decision making when taking a DA agonist.
Therefore, in the context of an 8-week, double-blind,
placebo-controlled trial of pramipexole for cognitive
enhancement in BPD (Burdick et al, 2012), we measured
emotional decision-making capacity before and after drug
administration in a subset of euthymic patients with BPD,
who completed the study using the Iowa Gambling Task
(IGT). The aim of the study was to test for effects of
pramipexole on decision making related to risk and reward
outcomes. We hypothesized that pramipexole would have a
deleterious effect on gambling task performance in patients
with BPD.
MATERIALS AND METHODS
Patient Participants
Data were collected between July 2006 and April 2010, in a
Stanley Medical Research Institute-funded, 8-week, double-
blind, placebo-controlled, adjunctive trial of pramipexole.
The study was approved by the North Shore-Long Island
Jewish Health System (NSLIJHS) Institutional Review Board
and was registered on clinicaltrials.gov (NCT00597896). All
participants signed informed consent before any study
procedure.
Fifty stable outpatients with a clinical diagnosis of bipolar
I or bipolar II disorder were randomized to the placebo or
the pramipexole condition. Forty-five subjects completed
the trial and were included in the primary analyses
investigating the effects of pramipexole on neurocognitive
functioning (Burdick et al, 2012). During the study, we
added a measure of emotional decision making (the IGT)
to our battery to more comprehensively assess side effects
associated with impulsive behaviors. The analyses of this
task, therefore, included a cohort of 34 patients who
completed both pre- and posttreatment assessments—
details on the full sample are available in Burdick et al
(2012). The IGT BPD sample had a mean age of 43.9±11.6
years, were 59% female, and 68% Caucasian. At baseline, the
sample had an estimated premorbid IQ of 100.8±9.0, a
mean Hamilton Depression Rating Scale (HAM-D) score of
5.1±2.9, and a mean Clinician Administered Rating Scale
for Mania (CARS-M) of 2.9±2.3—indicative of euthymia.
Again, at week 8 the BPD sample was euthymic with a mean
HAM-D score of 3.9±3.6 and a mean CARS-M score of
2.8±3.9. There were no clinical or demographic differences
between the IGT sample reported here and the full sample of
BPD subjects reported in Burdick et al 2012 (data not
shown).
All subjects were recruited from the Zucker Hillside
Hospital (ZHH-NSLIJHS) outpatient division. Individuals
who provided written informed consent were eligible to
participate in the investigation if there was no history of
CNS trauma, known neurological disorder, or learning
disability. In addition, patients who received a DSM-IV
diagnosis of current/recent substance abuse or dependence
(ie, within the past month) were excluded from participa-
tion. Participants were also excluded if their premorbid IQ
was estimated to be 80 or below on the WRAT Reading
subtest.
Although medication status is an important factor, given
the high prevalence of combination pharmacotherapy for
BPD, it was not practical to exclude patients who were
taking any medications. Rather, to help control for the
effects of medication on cognition, patients were excluded
from the analyses if they used a benzodiazepine, sedative, or
sleeping pill within 6 h of neurocognitive testing. Further-
more, patients taking medications that are known to
interact with pramipexole (eg, cimetidine) were excluded.
We recognize the potential for lithium, anticonvulsants,
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antidepressants, and antipsychotic medications to influence
cognitive performance, but it was not feasible to disallow
these medications given their widespread use in mood
stabilization. However, a stable regimen, for at least 4 weeks
before randomization with no medication/dosage changes
during the 8-week study period, was required for inclusion.
Measures
As part of their participation in the study, subjects were
administered a comprehensive assessment battery, at base-
line and at week 8, consisting of behavioral ratings, a
structured diagnostic interview, and a neurocognitive
battery. The full details on the neurocognitive assessment
are provided in Burdick et al (2012); the current study
focused on the single measure of emotional decision
making, the IGT, which is described below.
DSM-IV-based diagnoses were determined using the
Structured Clinical Interview for DSM-IV (SCID-IV). When
available, the subjects’ report was augmented by medical
records and collateral information from family members,
and the resulting data were presented to senior faculty,
residents, fellows, and other trained SCID raters at a weekly
diagnostic conference, to establish a consensus diagnosis.
The current severity of affective symptoms was assessed
weekly throughout the 8-week clinical trial using the
HAM-D (Hamilton, 1960) and the CARS-M (Altman et al,
1994). ZHH raters were trained to a high inter-rater
reliability (ICC40.80) on the administration of these scales.
The IGT (Bechara et al, 1994) was used to assess
emotional decision-making abilities. We chose this task
over other reward-based measures because of its face
validity in the context of pramipexole’s potential to induced
pathological gambling. It also represents a useful measure
in that it entails both gains and losses, incorporating both
positive and negative feedback. Specifically, in this task the
subject is asked to choose cards from four decks (100
choices in total), resulting in monetary gains or losses.
Decks A and B are disadvantageous (high risk–high reward)
in that the subjects obtain large immediate wins, but they
also attain intermittent large losses, resulting in a net overall
loss. In contrast, decks C and D are advantageous (low risk–
low reward) in that they result in smaller immediate gains
but lower long-term penalties and net an overall win.
Healthy volunteers are able to discern over 5 blocks (20
cards each) that choosing from decks C and D is most
beneficial, and a normal learning curve is typical over the 5
blocks (Bechara et al, 1994).
In addition to learning curve analyses on the IGT, an
expectancy valence (EV) model can be deployed for this
task to determine card-by-card strategy (Busemeyer and
Stout, 2002). This model results in three indices. Recency,
the learning rate parameter, reflects a person’s ability to use
information from prior trials to form expectancies based
upon probabilistic function. Healthy individuals typically
begin with a random choice approach until expectancies
develop, which can then be used to influence card selection.
Higher scores on this parameter indicate better expectancy-
based learning. Attention weight given to losses as opposed
to gains (Attention Losses/Gains)determines to what degree
a person uses feedback related to losing money versus
feedback regarding wins (gains) over the course of the task
to inform subsequent card choice. This is related to the
emotional reaction a person has when he/she wins or loses
(called a valence), from which is derived an attention weight
parameter that reflects a person’s relative attention to losses
and wins. When equal weight is given, the value is 0.5; when
losses are totally ignored and all choices are based on wins,
the value is 0, and likewise when only information related to
losses is attended to, the value is 1.0. Reliability, a marker of
choice consistency or erratic, impulsive choice behavior is a
measure of sensitivity. Increased sensitivity (higher scores)
indicate more consistent, less random card choice. The
current study utilized the learning curve and the three EV
indices as primary outcome measures for the IGT. The
description of this task as an ‘emotional’ decision-making
task is based upon this EV model; others have referred to
this measure as a reward-based decision-making task.
Data Analysis
Treatment groups were compared on basic demographic
and clinical variables using multivariate analysis of variance
and w2-test where appropriate.
To examine the effects of pramipexole on IGT perfor-
mance, the data were analyzed in two different ways. First,
NET scores were derived by subtracting the number of
cards chosen from advantageous decks from the total
chosen from the disadvantageous decks ((CþD) (AþB))
over the course of five blocks (trials 1–20 (NET 1), 21–40
(NET 2), 41–60 (NET 3), 61–80 (NET 4), and 81–100 (NET
5)). A repeated-measures (RM) ANCOVA was conducted
with Group (active drug vs placebo) serving as the between-
subjects factor; Time (baseline, week 8) as a two-level
within-subjects factor; and Block as a five-level within-
subjects factor. Covariates included age, change in HAM-D
ratings, and change in CARS-M ratings, and the main and
interaction effects are described below. To better under-
stand the pattern of performance that emerged, the card-by-
card strategy implemented by the two patient groups’
performance at baseline and at the conclusion of the 8-week
trial was then assessed. A series of three, RM-ANCOVAs
was conducted; Recency, Attention Losses/Gains, and
Reliability (consistency of response) served as the depen-
dent variables.
RESULTS
Treatment groups (placebo, n¼ 18; pramipexole, n¼ 16)
did not differ in age, premorbid IQ, race, or sex distribution
(Table 1). All subjects in the pramipexole arm reached
the maximum daily dosage (1.5mg/day) by week 4 and
remained at this dose for the duration of the 8 weeks. There
were no significant differences by treatment type with
regard to symptoms of depression or mania at baseline or
at week 8, and both groups were in the euthymic range at
the time of both assessments. There were nonsignificant
differences between groups with regard to the distribution
of bipolar subtype (I vs II) and prevalence of prior
substance-use history (no subject met current DSM-IV
criteria for abuse or dependence). Moreover, there were no
differences in the classes of psychotropic medications used
by subjects assigned to pramipexole vs those assigned to
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placebo (Table 1). Finally, the change in depression ratings
(HAM-D) from baseline to week 8 was comparable in the
active (mean change of 1.6±3.7) and the placebo (mean
change of 1.0±3.2) arms (F¼ 0.23; df¼ 1, 33; p¼ 0.64), as
was the change in mania symptoms (CARS-M) with a
pramipexole group mean change of  0.13±4.0 vs the
placebo group mean change of 0.44±3.1 (F¼ 0.27; df¼ 1,
33; p¼ 0.64). These change scores represent clinically
insignificant changes in affective symptoms over the 8-
week study period; however, we included change scores as
covariates in all models to ensure control for even a slight
variance in mood.
IGT Analyses by Block
A RM-ANCOVA revealed a significant main effect of Time
(F¼ 4.20; df¼ 1, 29; p¼ 0.05); a significant two-way
interaction of TimeBlock (F¼ 4.12; df¼ 4, 26;
p¼ 0.004); and a significant three-way interaction for
TimeBlockGroup (F¼ 3.49; df¼ 4, 26; p¼ 0.01). These
results survive the Bonferroni correction for multiple
testing corrected for the three factors included in the
model. There were no other significant main effects or
interactions (Table 2). Post-hoc tests of within-subject
contrasts for the TimeBlockGroup interaction were
significant for a linear trend (F¼ 8.45; df¼ 1, 29; p¼ 0.007).
Covariates/other variables of interest. When the model
was repeated without age and mood state change scores as
covariates, all results remained significant. In addition,
when sex was entered as a fixed factor, there were no
significant main or interaction effects and the three-way
interaction TimeBlockGroup remained significant.
Although groups did not differ on prior substance-use
disorders, given its potential to influence results we re-ran
the analysis including this as a factor and, again, the results
remained significant. Finally, in an effort to test for the
effects of concomitant medications on the results, we first
dichotomized patients based on the presence/absence of
lithium, antipsychotics, anticonvulsants, and antidepres-
sants. Although this is not ideal, it is the best way to capture
these variables in our data set. We ran the RM-ANOVA with
medication class as the between-subjects factor and found
no significant main effects of any of the medication classes.
To explicate the three-way interaction, we conducted
separate RM-ANCOVAs for baseline IGT performance and
for week 8 performance. For baseline analyses, we included
baseline ratings for depression (HAM-D) and mania
(CARS-M) as covariates. There were no significant main
effects and no significant interaction effects, indicating that
IGT performance did not differ by treatment group at baseline
(BlockGroup interaction: F¼ 0.63; df¼ 4, 27; p¼ 0.64;
Figure 1 left panel), with both patient groups showing
evidence of a blunted learning curve in comparison with
what is typically reported in healthy controls (Bechara et al,
1994). For week 8 analyses, we included HAM-D and CARS-M
scores at week 8 as covariates. After the 8-week treatment
period, results indicate a differential pattern of performance
in patients taking pramipexole vs those taking placebo
(GroupBlock interaction: F¼ 2.57; df¼ 4, 27; p¼ 0.04;
Figure 1, right panel). There were no other significant main
or interaction effects at week 8. The pattern of performance
after treatment indicated nonsignificant changes from base-
line to week 8 in the placebo condition, albeit with some
evidence of an improvement with a more normalized learning
curve, which may represent practice effects.
In contrast, patients on pramipexole evidenced a pattern
of performance over the five blocks akin to a reverse
learning curve. In other words, patients taking pramipexole
chose increasingly more disadvantageous choices vs ad-
vantageous choices over the five blocks, a pattern that is
opposite from what is normally seen in healthy individuals
(Bechara et al, 1994).
A small sample of healthy controls (n¼ 21) involved in a
separate study are depicted in the figures as a reference
sample for purposes of illustration. The healthy controls
Table 1 Characteristics of the Sample by Group
Placebo
(n¼18)
Pramipexole
(n¼16)
Stat p-value
Age (years) 44.9 (12.9) 42.7 (10.4) F¼ 0.31 0.58
% Female 61.1 56.3 w2¼ 0.08 0.77
% Caucasian 61.1 75.0 w2¼ 0.75 0.39
Bipolar I/bipolar II 13/5 11/5 w2¼ 0.05 0.82
% With past Substance
use D/O
50% 50% w2¼ 0.00 1.00
Premorbid IQ 100.8 (9.7) 100.9 (8.5) Fo0.01 0.98
Baseline HAM-D 4.7 (2.8) 5.6 (3.0) F¼ 0.85 0.37
Baseline CARS-M 2.3 (2.1) 3.7 (2.4) F¼ 3.26 0.08
Week-8 HAM-D 3.7 (3.5) 4.1 (3.9) F¼ 0.07 0.79
Week-8 CARS-M 1.8 (2.8) 3.8 (4.7) F¼ 2.27 0.14
% On antipsychotics 66.7 62.5 w2¼ 0.06 0.80
% On antidepressants 50.0 37.5 w2¼ 0.54 0.43
% On lithium 38.9 50.0 w2¼ 0.42 0.52
% On anticonvulsants 50.0 43.8 w2¼ 0.13 0.72
Table 2 R-MANCOVA Results
df F p-value
Time 1, 29 4.20 0.05*
Time age 1, 29 2.70 0.11
TimeHAM-D D 1, 29 0.03 0.87
TimeCARS-M D 1, 29 0.10 0.75
TimeGroup 1, 29 0.004 0.95
Block 4, 26 1.17 0.33
BlockHAM-D D 4, 26 0.60 0.67
BlockAge 4, 26 1.11 0.36
BlockCARS-M D 4, 26 0.86 0.49
BlockGroup 4, 26 0.27 0.90
Time Block 4, 26 4.12 0.004*
Time BlockHAM-D D 4, 26 0.90 0.47
Time BlockCARS-M D 4, 26 0.81 0.52
Time BlockGroup 4, 26 3.49 0.01*
p-value p0.05.
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had a mean age of 26.9±8.5 years, were 19% female, and
57% Caucasian. These subjects were not well-matched to
our BPD sample demographically and did not complete
repeat testing on the IGT; therefore, although their data are
provided graphically to depict ‘normal’ IGT performance
relative to BPD performance, they are not included in the
statistical analyses.
Practice effects have been documented in healthy
individuals on the IGT (Bechara et al, 2000) over at least
three repeated administrations (improvements seen on each
attempt). This is in contrast to what has been shown in
individuals with VM prefrontal cortex (PFC) lesions/
damage, where improvements are negligible (nonsignifi-
cant) over time and recovery (Waters-Wood et al, 2012).
The presence of practice effects in healthy samples has
made estimating reliability on this task difficult. One study
published in Brazil specifically addressed a test-retest
reliability of the IGT in healthy individuals and noted
‘moderately positive correlations’ for Blocks 4 and 5 but
weaker relationships in the earlier blocks (Cardoso et al,
2010). In an effort to address the issue of stability in our BD
sample, we conducted secondary analyses restricted to the
BD sample, to illustrate that as a group (all BD subjects)
there is relative stability of performance on Blocks 4 and 5
of the IGT (ICC¼ 0.49; p¼ 0.03). We then split the sample
based on treatment group and re-ran the reliability analyses
and find that the placebo group shows high stability in
Blocks 4 and 5 (ICC¼ 0.57; p¼ 0.04) but the subjects taking
pramipexole are less reliable over time (ICC¼ 0.36;
p¼ 0.20). Of note, despite higher stability of performance
in the placebo condition, these subjects show statistically
significant evidence of improvement (or practice effect) by
Block 5 (as per paired Student’s t-tests by block; t¼ 3.39;
df¼ 17; p¼ 0.003), whereas those subjects taking prami-
pexole not only failed to improve as expected by Block 5
(t¼ 0.55; df ¼ 15; p¼ 0.59), their performance actually
worsened.
IGT Analyses of Card-by-Card Strategy
A series of RM-ANCOVAs were then conducted to ascertain
whether pramipexole use affected the card-by-card strategy
implemented. Recency, Attention Losses/Gains, and Relia-
bility served as the two-level within-subjects-dependent
variables in these analyses. When including age, HAM-D
change score, and CARS-M change score as covariates in the
model, there were no significant main or interaction effects
for the Recency or the Reliability indices (data not shown).
In contrast, the analyses for the Attention Losses/Gains
parameter revealed a significant TimeGroup interaction
(F¼ 5.08; df¼ 1; p¼ 0.03). There were no other significant
main or interaction effects for this index. These results
suggest a change from baseline choice strategy to week 8
choice strategy such that subjects taking placebo attended
more to losses than to gains after the 8-week study,
performing more like a healthy control cohort. In contrast,
subjects taking pramipexole attended more to gains than to
losses after treatment (Figure 2). Follow-up MANOVA
indicated a significant group difference for change score on
the Attention Losses/Gains index (baseline scoreweek 8
score) consistent with this pattern (F¼ 6.01; df¼ 1, 29;
p¼ 0.02; placebo mean change score þ 0.17±0.37; prami-
pexole mean change score  0.11±0.26). When using the
healthy controls’ performance as a reference group (black
Figure 1 The Iowa Gambling Task (IGT) results by group pre- and post-treatment. Performance across five blocks on the IGT. The x-axis represents the
five blocks of the task, with the left panel marking the performance at baseline and the right panel marking the performance at week 8. A gray-scale rectangle
depicts the 8-week treatment trial, during which time no testing was conducted. The y-axis shows the NET score variable, which is calculated by subtracting
the total number of cards chosen from the disadvantageous decks from the total number of cards chosen from the advantageous decks.
Figure 2 Choice strategy: Attention to Losses vs Gains. The card-by-
card selection strategy employed with scores from the Attention Losses/
Gains index of the expectancy valence model. The x-axis is labeled for the
two time points (baseline and week 8), with the y-axis representing the
ratio of attention given to negative feedback information (losses) relative to
positive feedback (wins). Higher scores represent more attention to losses
than to gains.
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dotted line in Figure 2), the pattern of subjects taking
placebo after 8 weeks appears normal, whereas the subjects
taking pramipexole deviates further away from the normal
pattern of performance. Again, secondary analyses indi-
cated no main effects of concomitant medication on these
results.
DISCUSSION
To our knowledge, this is the first study to assess the effects
of a DA receptor agonist on emotional decision making in
patients with BPD. Our results suggest that after 8 weeks on
pramipexole, BPD subjects demonstrate impaired perfor-
mance on the IGT, consistent with prior reports of DA
agonist-induced impulse-control disorders (eg, pathological
gambling) in patients with PD (Dodd et al, 2005; Voon et al,
2006a, 2006b; Potenza et al, 2007; Lader, 2008; Bodi et al,
2009; Weintraub et al, 2006, 2010; Pontone et al, 2006). The
pattern of performance noted in the pramipexole group is
consistent with a reverse learning curve, indicating that over
the five blocks of the IGT, patients on pramipexole
increasingly chose cards from the disadvantageous decks,
the opposite from the pattern expected in healthy indivi-
duals (Bechara et al, 1994). High-risk, high-reward choice
preferences on a gambling task post-pramipexole treatment
were noted, despite no exacerbation in manic symptoms
and in the absence of any reported behavioral abnormal-
ities.
Results from the EV model suggest that the poor
performance in the pramipexole group at week 8 might be
explained by the patients’ over-reliance on feedback related
to winning money (gains) when making card choices. Both
patient groups showed a tendency to attend more readily
to gains vs losses at baseline, which is consistent with a
hypothesized reduced sensitivity to reward (Chandler et al,
2009). However, after treatment, BPD subjects who were
assigned to the placebo condition attended more equally to
positive and negative feedback, similar to patterns noted in
healthy individuals. This improvement in the placebo
condition is most likely reflective of practice effects related
to a familiarity with the task. In contrast, BPD patients
who had been on 8 weeks of pramipexole evidenced an
exaggerated tendency to ignore loss information with a
greater regard for feedback indicating wins.
These data are consistent with a substantial literature on
the BAS and its relationship with mania and BPD (for
review, see Johnson et al, 2012). In general, evidence
suggests that patients with BPD are willing to expend more
effort toward rewarding stimuli and increase goal pursuit
following an initial reward. Experimental methods used to
amplify activity in the incentive salience system, through
knockout of the DA transporter gene or via administration
of amphetamine, not only result in behavioral changes
consistent with mania but also enhance an animal’s
willingness to expend effort toward reward without altering
other aspects of learning (Berridge, 2007).
These results are also consistent with prior reports of
compulsive gambling in patients with PD after clinical
treatment with pramipexole and similar agents (Aiken,
2007). Several neuroimaging studies have attempted to
elucidate the effect that pramipexole has on reward
processing in the context of single-dose challenge para-
digms in both PD patients and in healthy subjects. In a
study of healthy males, Riba et al (2008) showed a blunted
activation in the rostral basal ganglia and midbrain,
following an unexpected monetary gain 2 h after adminis-
tration of 0.5mg of pramipexole vs a placebo. Similarly, a
decrease in the correlation between reward prediction error
and BOLD response was observed in the orbitofrontal
cortex and striatum in early-stage PD patientsB1–2 h after
administration of 1.0mg of pramipexole (van Eimeren et al,
2009), suggesting impairment in reward circuitry. A recent
functional connectivity analysis of healthy males demon-
strated that pramipexole increases activity in the nucleus
accumbens and weakens connectivity between this structure
and the PFC during reward anticipation (Ye et al, 2011).
Taken together, these data suggest that pramipexole induces
abnormal activation patterns and connectivity within the
neural circuitry critical to reward-based learning, an action
that is likely to explain the IGT data in our BPD patients. It
remains possible, of course, that the changes noted on the
IGT performance in our cohort were related to some
unknown third variable and were not direct effects of the
drug; however, given the matching of the treatment groups
at both baseline and week 8, we believe that this is an
unlikely explanation.
Pramipexole is a partial/full D2/D3 agonist with selective
affinity for DA receptors of the D2 subfamily (Antonini and
Calandrella, 2011). Unlike psychostimulant medications, it
has an eightfold greater affinity for D3 over the D2 receptor
(Mierau et al, 1995; Gerlach et al, 2003) and it acts on
presynaptic and on postsynaptic receptors (Piercey, 1998).
In intact dopaminergic systems and at lower doses,
pramipexole primarily stimulates presynaptic autoreceptors
of the D3 and D2 type, thereby reducing the synthesis
and synaptic release of DA. Stimulation of D2 and D3
postsynaptic receptors is observed with reduced DA release
due to loss or damage of the presynaptic terminations
(Mierau et al, 1995). Specifically, in patients with PD,
pramipexole imparts its therapeutic effects on motor
deficits through the postsynaptic D2 and D3 receptors to
correct an imbalance between the direct and the indirect
striatofugal nerve tracts by enhancing the direct transmis-
sion (through D3 receptors) and reducing the indirect
transmission (through D2 receptors; (Mierau et al, 1995)).
Pramipexole’s relative specificity allows for a unique
opportunity to enhance DA in phylogenetically older
regions of the brain that are associated with emotion
regulation and cognitive function (Camacho-Ochoa et al,
1995). Consistent with this mechanism of action, pramipex-
ole has a direct antidepressant effect in patients with PD
(Leentjens et al, 2009) above and beyond its efficacy for
motor symptoms associated with the illness (Barone et al,
2010). This antidepressant effect has also been noted in
mood-disordered patients (Aiken, 2007), including patients
with BPD (Goldberg et al, 2004; Zarate et al, 2004). Of
particular relevance, preclinical data suggest a neurotrophic
effect of pramipexole in models of neurodegenerative
disorders (Lauterbach et al, 2010), which is in part mediated
by the anti-apoptotic protein bcl-2 (Takata et al, 2000). In
line with these beneficial effects of pramipexole, but
somewhat contrary to the IGT data described here, we
recently reported an improvement on measures of attention
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and working memory in this same cohort after pramipexole
treatment (Burdick et al, 2012), suggestive of a pro-
cognitive effect of this agent in euthymic BPD patients.
One potential explanation for these contradictory effects
might be related to the action of pramipexole at both the D2
and the D3 receptor sites. Although the primary binding site
for pramipexole is the D3 receptor, its affinity to the D2
receptor remains high (Kvernmo et al, 2006). D2 receptors
are localized to several brain regions that are critical to
higher-order cognitive control (van Holstein et al, 2011),
and D2 agonists such as bromocriptine have demonstrated
pro-cognitive effects in healthy individuals (Kimberg et al,
1997; Luciana et al, 1998), particularly in cognitive domains
linked to PFC functions. We would hypothesize that
pramipexole’s activity at the D2 receptors could readily
explain enhancement on attention and working memory
tasks that are closely linked with the availability of DA in
the PFC (Badre, 2012). In contrast, D3 receptors are most
widely distributed in regions involved in reward-based
learning (Beninger and Banasikowski, 2008), which might
be more directly relevant for task performance on
emotional decision-making measures, such as the IGT. D3
receptors are primarily expressed in the mesocorticolimbic
DA pathway, and structures in this circuitry show increased
activation during impulsive decision making (see Madden
et al, 2010 for review). D3 receptors are involved in phasic,
not tonic, DA signaling, suggesting an important role for the
D3 receptor in modulating the emotional experience of
novelty, reward, and risk assessment (Kelley et al, 2012).
As this study was primarily focused on the potential
cognitive enhancing properties of pramipexole and was not
specifically designed to test for deleterious effects on
emotional decision making, only a subset of our sample
completed the IGT at both time points. This resulted in a
smaller sample size with reduced power; nonetheless, even
in a relatively small cohort, we were able to detect a
significant three-way interaction effect, indicating an effect
of pramipexole on reward-based learning in BPD. In
addition, all of our BPD subjects were medicated at the
time of assessment and most were taking more than one
psychotropic medication, making stratification for conco-
mitant medication status unfeasible. Future, larger-scale
studies will be important in determining the effects of other
medications on these results. Finally, we did not conduct
any neuroimaging with these subjects and, therefore, cannot
determine with any certainty the mechanism by which
pramipexole may simultaneously act to enhance certain
aspects of neurocognitive functions and to impair reward-
based learning.
In summary, we report a novel finding of abnormal
reward-related decision making after treatment with the
D2/D3 agonist, pramipexole, in patients with BPD. This is
the first study to describe the reward-based effects of
pramipexole in the context of a controlled clinical trial; our
results are consistent with prior work in single-dose studies
of healthy subjects and patients with PD. Future studies
should address the potential clinical implications of our
findings over a longer duration. Although we found no
evidence of increased mania or impulsive behaviors in our
cohort, it is possible that the deficits noted on the IGT could
serve as markers of impending affective instability that
could not be fully captured in an 8-week study. Additional
work in understanding the relative benefits and deleterious
effects of dopaminergic agents in BPD will be important in
guiding future treatment efforts targeting neurocognition as
an outcome.
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